CASE COMMENTS: UNILATERAL PRACTICES – FRANCE – COLLECTIVE DOMINANT POSITION – DENIGRATION – INTERVENTION BEFORE HEALTH AUTHORITIES

Collective dominant position: The French Competition Authority sanctions three pharmaceutical companies for denigration practices and for spreading alarmist, even misleading, discourse to public authorities (Novartis, Roche, Genentech)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. In a decision of September 9, 2020, the French Competition Authority ("the Authority") sanctioned Novartis, Roche and Genentech for abusive practices aimed at safeguarding sales of the drug Lucentis for the treatment of age-related macular degeneration ("AMD") to the detriment of the drug Avastin for an amount of €444 million. Significantly, these three laboratories have already been fined a total of EUR 182.5 million by the Italian competition authority for similar events in Italy (decision of 27 February 2014 of theAutorita Garante della Concorrenza e del Mercato, 'the Italian Case'). The drugs Avastin and Lucentis, developed by the Genentech laboratory

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Anne Wachsmann, Nicolas Zacharie, Collective dominant position: The French Competition Authority sanctions three pharmaceutical companies for denigration practices and for spreading alarmist, even misleading, discourse to public authorities (Novartis, Roche, Genentech), 9 September 2020, Concurrences N° 4-2020, Art. N° 97563, pp. 137-141

Visites 48

All reviews